BridgeBio Pharma
BBIO
178 hedge funds and large institutions have $1.45B invested in BridgeBio Pharma in 2022 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 49 increasing their positions, 59 reducing their positions, and 57 closing their positions.
144% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $4.17M
0.57% more ownership
Funds ownership: 96.51% → 97.08% (+0.57%)
9% less funds holding
Funds holding: 195 → 178 (-17)
17% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 59
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 57
39% less capital invested
Capital invested by funds: $2.37B → $1.45B (-$913M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$58.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$12.6M |
| 3 |
D.E. Shaw & Co
New York
|
+$12.4M |
| 4 |
Morgan Stanley
New York
|
+$7.82M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$7.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$33.8M |
| 2 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$16.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$12.7M |
| 4 |
Rockefeller Capital Management
New York
|
-$10.5M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$8.24M |
BBIO Hedge Fund Activity: Q1 2022 in Review
178 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2022, worth a combined $1.45B — down 39% from $2.37B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of BBIO and 43 opened new positions — a net loss of 14 holders — while 59 trimmed existing stakes and 49 added.
The largest buyer was State Street, adding an estimated $58.3M. The largest seller was Perceptive Advisors, cutting an estimated $33.8M.
- 178 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2022, down from 195 in Q4 2021.
- Funds reported $1.45B of BridgeBio Pharma stock for Q1 2022, down 39% quarter-over-quarter.
- 43 funds opened new BridgeBio Pharma positions in Q1 2022 and 57 closed out, a net change of -14 holders.
- The largest BridgeBio Pharma buyer in Q1 2022 was State Street, an estimated $58.3M added.
- The largest BridgeBio Pharma seller in Q1 2022 was Perceptive Advisors, an estimated $33.8M sold.
Based on aggregated 13F filings for Q1 2022.